Key result
In a rat model of chronic kidney disease, tissue levels of phylloquinone (K1) were significantly lower in liver, spleen, and heart, while menaquinone-4 (MK-4) levels were higher in the kidney.
Why the study?
Does chronic kidney disease alter vitamin K metabolism and tissue concentrations in a rat model?
Does chronic kidney disease alter vitamin K metabolism and tissue concentrations in a rat model?
Chronic kidney disease alters vitamin K metabolism early in the disease course, suggesting that sub-clinical vitamin K deficiency may be a modifiable risk factor for vascular and bone health.
Suggests early vitamin K dysregulation in CKD; hypothesis-generating for human supplementation trials targeting vascular risk.
BACKGROUND: Patients with chronic kidney disease (CKD) have very high levels of uncarboxylated, inactive, extra-hepatic vitamin K-dependent proteins measured in circulation, putting them at risk for complications of vitamin K deficiency. The major form of vitamin K found in the liver is phylloquinone (K1). Menaquinone-4 (MK-4) is the form of vitamin K that is preferentially found in extra-hepatic tissues. METHODS: In the present study, we assessed tissue concentrations of K1 and MK-4 and the expression of vitamin K-related genes in a rat model of adenine-induced CKD. RESULTS: It was found that rats with both mild and severe CKD had significantly lower amounts of K1 measured in liver, spleen and heart and higher levels of MK-4 measured in kidney cortex and medulla. All animals treated with high dietary K1 had an increase in tissue levels of both K1 and MK-4; however, the relative increase in K1 differed suggesting that the conversion of K1 to MK-4 may be a regulated/limiting process in some tissues. There was a decrease in the thoracic aorta expression of vitamin K recycling (Vkor) and utilization (Ggcx) enzymes, and a decrease in the kidney level of vitamin K1 to MK-4 bioconversion enzyme Ubiad1 in CKD. CONCLUSION: Taken together, these findings suggest that CKD impacts vitamin K metabolism, and this occurs early in the disease course. Our findings that vitamin K metabolism is altered in the presence of CKD provides further support that sub-clinical vitamin K deficiency may represent a modifiable risk factor for vascular and bone health in this population.
No takes yet. Share an insight, caveat, or question.
McCabe et al. (2016) studied Chronic Kidney Disease. High dietary K1 was evaluated on Tissue concentrations of K1 and MK-4 and expression of vitamin K-related genes. In a rat model of chronic kidney disease, tissue levels of phylloquinone (K1) were significantly lower in liver, spleen, and heart, while menaquinone-4 (MK-4) levels were higher in the kidney.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: